Company Product Description Indication Status
Phase I
Ico Therapeutics Inc., of Vancouver, British Columbia Amphotericin B Lipophilic molecule Vulvovaginal candidiasis All subjects in first of 2 cohorts in phase Ib study have received 100-mg doses over 10 days, with no drug-related adverse events observed to date; 1 additional cohort is expected to be dosed in early Q1 2020, followed by initiation of a phase II study comparing oral Amphotericin B to fluconazole in a head-to-head study 
Mateon Therapeutics Inc., of Agoura Hills, Calif. OXi-4503 Cis-combretastatin A1 dipotassium diphosphate Acute myeloid leukemia Study in 26 evaluable patients with previously treated relapsed AML met primary endpoint; adding Combretastatin A1 to standard chemotherapy cytarabine was generally well-tolerated and maximum tolerated dose was identified as recommended dose for further clinical work
Phase III
Acasti Pharma Inc., of Laval, Quebec Capre Omega-3 phospholipid Severe hypertriglyceridemia Top-line results for Trilogy 1 pivotal trial expected in January due to unexpected delay in data processing and transfer from central testing laboratory to the statistical consultants for independent and external validation

Notes

For more information about individual companies and/or products, see Cortellis.

No Comments